Oncology Archives - Page 8 of 22

Injectable hypomethylating agents for management of myelodysplastic syndromes: patients’ perspectives on treatment

Authors: A M Zeidan, S Jayade, J Schmier, M Botteman, A Hassan, D Ruiters, K Hill, N Joshi Published: Clinical Lymphoma, Myeloma and Leukemia, 2022 View publication Background Until recently, patients with...

Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study

Authors: H Malik, A Z Khan, D P Berry, I C Cameron, I Pope, D Sherlock, S Helmy, B Byrne, M Thompson, A Pulfer, B Davidson Published: European Journal of Surgical Oncology,...

Modern chemotherapy management of recurrent ovarian cancer: a multicentre study

Authors: S Chan, M Griffin, J Stewart, K Gregory, A Hughes, S Awwad, R Allerton, S Pledge, H Thomas, F Percival, Ovarian Cancer Audit Group UK Published: Clinical Oncology, 2007 View publication...

Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma

Authors: N Nathwani, J Bell, D Cherepanov, F G Sowell, R Shah, K McCarrier, P Hari Published: Supportive Care in Cancer, 2022 View publication Purpose This study aimed to better understand the...

Personalized cancer medicine in the media: sensationalism or realistic reporting?

Authors: K Hicks-Courant, J Shen, A Stroupe, A Cronin, E F Bair, S E Wing, E Sosa, R H Nagler, S W Gray Published: Journal of Personalized Medicine, 2021 View publication Background...

Psychometric validation of the EORTC QLQ-HCC18 in patients with previously treated unresectable hepatocellular carcinoma

Authors: D Serrano, L Podger, G Barnes, J Song, B Tang Published: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2022 View...

Quality-Adjusted survival with combination nab-paclitaxel+gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis

Authors: M Reni, Y Wan, C Solem, S Whiting, X Ji, M Botteman Published: Journal of Medical Economics, 2014 View publication Objectives To use the Quality-Adjusted Time Without Symptoms or Toxicities (Q-TWiST)...

Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States

Authors: A Hussain, S Jiang, D Varghese, S Appukkuttan, N Kebede, K Gnanasakthy, C Macahilig, R Waldeck, S Corman Published: BMC cancer, 2022 View publication Background Second-generation androgen receptor inhibitors (ARIs) have...

Real-world comparison of healthcare resource utilization and costs of [177 Lu]Lu-DOTA-TATE in patients with progressive neuroendocrine tumors in England: a matched cohort analysis using data from the hospital episode statistics dataset

Authors: T Cox, M O'Connell, O Leeuwenkamp, S Palimaka, N Reed Published: Current medical research and opinion, 2022 View publication Objective To explore the healthcare resource utilization (HCRU) and costs for patients...

News